Biomarker News and Research

RSS

A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule.

Corgenix Medical issued additional U.S. patent covering AspirinWorks technology

Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, has been issued an additional U.S. patent covering its AspirinWorks technology and product line.

25 Jun 2010

Impact of oil spill on humans and wildlife

University of Rhode Island Pharmacy Professor Bongsup Cho knows there are cancer-causing chemicals in diesel fumes and cigarette smoke.

25 Jun 2010

USPTO grants Tethys key patent for PreDx Diabetes Risk Score test

Tethys Bioscience, Inc., a privately held company, announced today that the United States Patent and Trademark Office has granted the Company US Patent 7,723,050. The patent is directed to the company's groundbreaking PreDx™ Diabetes Risk Score (DRS) test and relates to proprietary methods for assessing the risk of developing a diabetic condition.

24 Jun 2010

AVIS donates health research project focuses on cancer biomarkers

The greatest research project on cancer biomarkers is to start in the next months. The new scientific research will open new frontiers in the field of prevention of two most relevant cancer: prostate cancer and ovarian cancer. The research project, which also includes an important prevention programme, is named "AVIS donates health" (AVIS is the Italian most important blood donors association) and is supported by Fondazione Abo - Application of biotechnologies in Oncology, Avis, Lilt (Italiana League for the fight against cancer) and by the three scientific societies of gynecologists and urologists.

24 Jun 2010

Diet with high fructose, trans fats lead to fatty liver disease with scar tissue

Scientists at Cincinnati Children's Hospital Medical Center have discovered that a diet with high levels of fructose - levels equivalent to that in high fructose corn syrup - and of trans fats not only increases obesity, but also leads to significant fatty liver disease with scar tissue.

23 Jun 2010

Additional results from BLISS-52 Phase 3 trial of BENLYSTA for SLE to be presented at EULAR 2010

Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced the presentation of additional results from BLISS-52, one of two pivotal Phase 3 trials of BENLYSTA (belimumab) in seropositive patients with systemic lupus erythematosus. The additional data will be presented in Rome at the 2010 Congress of the European League against Rheumatism on Saturday, June 19.

18 Jun 2010

Completion of drug analysis by PBS-Bio enables PharmaGap advance development of novel anti-cancer drug

Predictive Biomarker Sciences Inc. (PBS-Bio) has completed its first drug analysis, enabling Canadian biotech company PharmaGap Inc. to significantly advance a potentially significant anti-cancer medication.

18 Jun 2010

Researchers identify how obese people become salt sensitive, hypertensive

One way obese people become salt sensitive and hypertensive has been identified by Medical College of Georgia researchers.

18 Jun 2010

Bone samples act as the ultimate biomarker for environmental pollution: Researchers

Exposure to chemical pollutants is of growing concern to regulators, health workers, and environmentalist groups alike. Now, researchers in the US and Russia have demonstrated that samples of human bone can act as a biological marker for dozens of metals and toxic elements across the periodic table. They describe details in a study published in the International Journal of Environment and Health.

18 Jun 2010

Research identifies early biomarker for insulin resistance, glucose intolerance in nondiabetic population

Metabolon, Inc., the leader in metabolomics-based biomarker discovery and analysis, today announced the publication of research that identified a novel, early biomarker for insulin resistance and glucose intolerance in a nondiabetic population.

17 Jun 2010

HGS, GSK announce full presentation of BLISS-76 Phase 3 BENLYSTA trial results for SLE at EULAR 2010

Human Genome Sciences, Inc. and GlaxoSmithKline PLC (GSK) today announced the full presentation of results from BLISS-76, one of two pivotal Phase 3 trials of BENLYSTA® (belimumab) in seropositive patients with systemic lupus erythematosus (SLE). The results will be presented today in Rome at the 2010 Congress of the European League Against Rheumatism (EULAR).

17 Jun 2010

Gamma-Dynacare to implement SQI's SQiDworks diagnostics platform

SQI Diagnostics Inc., a medical systems company focused on evolving laboratory-based biomarker testing, today announced that Gamma-Dynacare Medical Laboratories, one of Canada's largest providers of laboratory services, has agreed to put into operation SQI's SQiDworks(TM) platform, and to purchase SQI's multiplexed IgXplex(TM) Rheumatoid Arthritis consumables to meet its commercial needs.

17 Jun 2010

New biomarker study explores early detection of ovarian cancer

Despite many research advances, ovarian cancer remains lethal in a majority of cases, due to late diagnosis of the disease. In a new study, Dr. Joshua LaBaer of the Biodesign Institute at Arizona State University, along with Arturo Ramirez and Paul Lampe, researchers at the Fred Hutchinson Cancer Research Center in Seattle, used a novel method for identifying biomarkers-proteins in blood that can identify ovarian cancer before symptoms appear.

17 Jun 2010

AVEO granted patents for tests to identify cancer patients likely to respond to tivozanib

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the issuance of U.S. Patent Nos. 7,615,353, which issued in November 2009, and 7,736,861, which issued yesterday.

16 Jun 2010

Clinical trial to examine use of biomarkers to advance treatment of malignant gliomas launched

The Brain Tumor Unit at the Moores UCSD Cancer Center at the University of California, San Diego in La Jolla, is launching a clinical trial that will examine the use of biomarkers to advance the treatment of malignant gliomas, brain tumors that start in the brain or spinal cord tissue. Annually, about 17,000 Americans are diagnosed with gliomas, which are difficult to treat and often fatal.

16 Jun 2010

Prostate cancer deaths are expected to jump 17%: 2010 statistics

Prostate cancer deaths are expected to jump 17 percent this year, according to estimates based on National Cancer Institute data. The alarming 2010 statistics, just prior to Father's Day, has ZERO – The Project to End Prostate Cancer urging families to encourage Dad to get tested for the disease this Father's Day because prostate cancer is the second leading cancer among American men.

16 Jun 2010

Expected 97% accuracy in ovarian cancer detection: Study underway

Now scientists in Melbourne have found a more effective test to detect ovarian cancer and hope to commence trials soon. This new test will check for two additional biomarkers that may indicate ovarian cancer in addition to conventional tests.

15 Jun 2010

CDI, Promega enter collaboration for toxicity testing in drug discovery process

Cellular Dynamics International (CDI) and Promega have entered into a research collaboration with the goal of bringing more relevant and highly predictive toxicity testing to the drug discovery process. Pharmaceutical discovery scientists will now be able to combine bioassays with human cardiomyocytes to improve prediction of unintentional, detrimental side effects that have previously remained undetected until late in the development process or after release of the drug to the general public.

15 Jun 2010

Orasi Medical signs agreement to study effect of Lundbeck CNS compounds on human brain

Orasi Medical today announced that it has entered an agreement with H. Lundbeck A/S to study the effect of Lundbeck central nervous system compounds on the human brain.

15 Jun 2010

Clinical Data closes public offering of newly issued shares of common stock

Clinical Data, Inc. today announced the closing of its previously announced public offering of 2,237,412 newly issued shares of common stock, including 291,836 shares sold pursuant to the full exercise of an over-allotment option granted to the underwriters, at a price to the public of $14.30 per share.

15 Jun 2010

Biomarker News and Research

Further Reading

Corgenix Medical issued additional U.S. patent covering AspirinWorks technology

Impact of oil spill on humans and wildlife

USPTO grants Tethys key patent for PreDx Diabetes Risk Score test

AVIS donates health research project focuses on cancer biomarkers

Diet with high fructose, trans fats lead to fatty liver disease with scar tissue

Additional results from BLISS-52 Phase 3 trial of BENLYSTA for SLE to be presented at EULAR 2010

Completion of drug analysis by PBS-Bio enables PharmaGap advance development of novel anti-cancer drug

Researchers identify how obese people become salt sensitive, hypertensive

Bone samples act as the ultimate biomarker for environmental pollution: Researchers

Research identifies early biomarker for insulin resistance, glucose intolerance in nondiabetic population

HGS, GSK announce full presentation of BLISS-76 Phase 3 BENLYSTA trial results for SLE at EULAR 2010

Gamma-Dynacare to implement SQI's SQiDworks diagnostics platform

New biomarker study explores early detection of ovarian cancer

AVEO granted patents for tests to identify cancer patients likely to respond to tivozanib

Clinical trial to examine use of biomarkers to advance treatment of malignant gliomas launched

Prostate cancer deaths are expected to jump 17%: 2010 statistics

Expected 97% accuracy in ovarian cancer detection: Study underway

CDI, Promega enter collaboration for toxicity testing in drug discovery process

Orasi Medical signs agreement to study effect of Lundbeck CNS compounds on human brain

Clinical Data closes public offering of newly issued shares of common stock

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest Life Science News